Literature DB >> 20544208

Adjuvant radiotherapy following total mesorectal excision for stage IIA rectal cancer: is it beneficial?

Jin Soo Kim1, Nam Kyu Kim, Byung Soh Min, Hyuk Hur, Joong Bae Ahn, Ki Chang Keum.   

Abstract

PURPOSE: The benefit of adjuvant radiotherapy in patients with stage IIA (T3N0) rectal cancer following total mesorectal excision (TME) is controversial. We evaluated the effect of adjuvant chemoradiotherapy (CRT) versus chemotherapy (CT) alone on the local recurrence and survival of patients with stage IIA rectal cancer after TME.
METHODS: Between 1996 and 2004, patients with stage IIA rectal cancer who received adjuvant CT (n = 29) or CRT (n = 122) following TME were enrolled. Oncologic outcomes were compared between groups, and risk factors for local recurrence and overall survival rates were analyzed.
RESULTS: The median follow-up period was 78 months. No significant differences were observed in the 5-year local recurrence (3.4% versus 9.0%; P = 0.348) or 5-year overall survival rates (86.2% versus 80.3%; P = 0.924) between CT and CRT. However, involvement of the circumferential resection margin and age >60 years were associated with adverse oncologic outcomes.
CONCLUSIONS: Additional postoperative radiotherapy did not alter local recurrence or survival after TME in patients with stage IIA rectal cancer. Postoperative radiation may be an overtreatment as an adjuvant therapy in patients with stage IIA rectal cancer if they had no other risk factors. However, randomized controlled trials are warranted to confirm this suggestion.

Entities:  

Mesh:

Year:  2010        PMID: 20544208     DOI: 10.1007/s00384-010-0970-1

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  40 in total

1.  Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer.

Authors:  A Wibe; P R Rendedal; E Svensson; J Norstein; T J Eide; H E Myrvold; O Søreide
Journal:  Br J Surg       Date:  2002-03       Impact factor: 6.939

2.  Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)

Authors:  E Mamounas; S Wieand; N Wolmark; H D Bear; J N Atkins; K Song; J Jones; H Rockette
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

3.  Long-term effect of preoperative radiation therapy on anorectal function.

Authors:  Johan Pollack; Torbjörn Holm; Björn Cedermark; Bo Holmström; Anders Mellgren
Journal:  Dis Colon Rectum       Date:  2006-03       Impact factor: 4.585

4.  Outcome of anterior resection for stage II rectal cancer without radiation: the role of adjuvant chemotherapy.

Authors:  Wai Lun Law; Judy W C Ho; Raymond Chan; Gordon Au; Kin Wah Chu
Journal:  Dis Colon Rectum       Date:  2005-02       Impact factor: 4.585

5.  Long-term functional and quality of life outcomes after coloanal anastomosis for distal rectal cancer.

Authors:  Imran Hassan; David W Larson; Robert R Cima; Janette U Gaw; Heidi K Chua; Dieter Hahnloser; John M Stulak; Megan M O'Byrne; Dirk R Larson; Bruce G Wolff; John H Pemberton
Journal:  Dis Colon Rectum       Date:  2006-09       Impact factor: 4.585

6.  Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial.

Authors:  Corrie A M Marijnen; Cornelis J H van de Velde; Hein Putter; Mandy van den Brink; Cornelis P Maas; Hendrik Martijn; Harm J Rutten; Theo Wiggers; Elma Klein Kranenbarg; Jan-Willem H Leer; Anne M Stiggelbout
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

7.  Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.

Authors:  N Wolmark; H S Wieand; D M Hyams; L Colangelo; N V Dimitrov; E H Romond; M Wexler; D Prager; A B Cruz; P H Gordon; N J Petrelli; M Deutsch; E Mamounas; D L Wickerham; E R Fisher; H Rockette; B Fisher
Journal:  J Natl Cancer Inst       Date:  2000-03-01       Impact factor: 13.506

8.  Risk factors for faecal incontinence after rectal cancer treatment.

Authors:  M M Lange; M den Dulk; E R Bossema; C P Maas; K C M J Peeters; H J Rutten; E Klein Kranenbarg; C A M Marijnen; C J H van de Velde
Journal:  Br J Surg       Date:  2007-10       Impact factor: 6.939

9.  Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997.

Authors:  R J Heald; B J Moran; R D Ryall; R Sexton; J K MacFarlane
Journal:  Arch Surg       Date:  1998-08

10.  Local recurrence after potentially curative resection for rectal cancer in a series of 1008 patients.

Authors:  F T McDermott; E S Hughes; E Pihl; W R Johnson; A B Price
Journal:  Br J Surg       Date:  1985-01       Impact factor: 6.939

View more
  9 in total

1.  Rectal cancer patients after neoadjuvant radiotherapy (30Gy/10f) with negative lymph node may not benefit from postoperative adjuvant chemotherapy: a retrospective study.

Authors:  Pengju Chen; Yunfeng Yao; Jin Gu
Journal:  Int J Colorectal Dis       Date:  2015-08-18       Impact factor: 2.571

2.  Neoadjuvant chemo-radiotherapy for cT3N0 rectal cancer: any benefit over upfront surgery? A propensity score-matched study.

Authors:  Luca Sorrentino; Marcello Guaglio; Luigi Battaglia; Giuliano Bonfanti; Marco Vitellaro; Alessandro Cesa Bianchi; Massimo Milione; Filiberto Belli
Journal:  Int J Colorectal Dis       Date:  2019-11-18       Impact factor: 2.571

3.  Patterns of care and outcomes for adjuvant treatment of pT3N0 rectal cancer using the National Cancer Database.

Authors:  Thomas J Quinn; Malolan S Rajagopalan; Beant Gill; Shabnam M Mehdiabadi; Peyman Kabolizadeh
Journal:  J Gastrointest Oncol       Date:  2020-02

4.  The importance of a multidisciplinary team in rectal cancer management.

Authors:  Ovidiu Vasile Bochis; Zsolt Fekete; Catalin Vlad; Bogdan Fetica; Daniel Corneliu Leucuta; Constantin Ioan Busuioc; Alexandru Irimie
Journal:  Clujul Med       Date:  2017-07-15

5.  A Prognostic Nomogram for T3N0 Rectal Cancer After Total Mesorectal Excision to Help Select Patients for Adjuvant Therapy.

Authors:  Chao Zhang; Shutao Zhao; Xudong Wang
Journal:  Front Oncol       Date:  2021-11-25       Impact factor: 6.244

6.  Effectiveness of radiotherapy for local control in T3N0 rectal cancer managed with total mesorectal excision: a meta-analysis.

Authors:  Michael Jonathan Kucharczyk; Andrew Bang; Michael C Tjong; Stefania Papatheodorou; Jesus C Fabregas
Journal:  Oncotarget       Date:  2022-10-08

7.  Interval between Surgery and Radiation Therapy Is an Important Prognostic Factor in Treatment of Rectal Cancer.

Authors:  Jin Hee Kim; Sang Jun Byun; Seung Gyu Park; Young Kee Oh; Seong Kyu Baek
Journal:  Cancer Res Treat       Date:  2012-09-30       Impact factor: 4.679

8.  In the era of total mesorectal excision: adjuvant radiotherapy may be unnecessary for pT3N0 rectal cancer.

Authors:  Jun-xin Wu; Yu Wang; Na Chen; Lu-chuan Chen; Peng-gang Bai; Jian-ji Pan
Journal:  Radiat Oncol       Date:  2014-07-22       Impact factor: 3.481

9.  Radiotherapy for stage IIA rectal cancer may not benefit all.

Authors:  Xiang Hu; Ya-Qi Li; Qing-Guo Li; Yan-Lei Ma; Jun-Jie Peng; San-Jun Cai
Journal:  Oncotarget       Date:  2017-07-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.